Drugs / epoetinum beta
epoetinum beta
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00551603 | Jul 2006 → Dec 2008 | — | Anemia Working Group Romania | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | epoetinum beta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00551603 ↗ |
| Known as | epoetin beta | “The Gain effectiveness in Anaemia treatment wIth NeoRecormon (epoetin beta) study (GAIN) evaluated the effectiveness and safety of recombinant human erythropoietin beta in...” PMID 19254204 ↗ Apr 2009 |
| Known as | NeoRecormon | “The Gain effectiveness in Anaemia treatment wIth NeoRecormon (epoetin beta) study (GAIN) evaluated the effectiveness and safety of recombinant human erythropoietin beta in...” PMID 19254204 ↗ Apr 2009 |
| Known as | recombinant human erythropoietin beta | “The Gain effectiveness in Anaemia treatment wIth NeoRecormon (epoetin beta) study (GAIN) evaluated the effectiveness and safety of recombinant human erythropoietin beta in...” PMID 19254204 ↗ Apr 2009 |
| Modality | Protein / enzyme biologic | “recombinant human erythropoietin beta” PMID 19254204 ↗ Apr 2009 |
| Route | Subcutaneous | “once-weekly SC epoetinum beta” NCT00551603 ↗ |